ID NZM019 AC CVCL_D822 SY NZM19 DR Cosmic; 2007656 DR Wikidata; Q54931540 RX CelloPub=CLPUB00227; RX PubMed=20041153; RX PubMed=23658559; RX PubMed=32567790; CC Doubling time: 63.1 hours (CelloPub=CLPUB00227). CC Omics: Transcriptomics; Microarray. ST Source(s): PubMed=32567790 ST Amelogenin: X,Y ST CSF1PO: 11 ST D13S317: 10,11 ST D16S539: 11,12 ST D18S51: 11,12 ST D19S433: 13,14 ST D21S11: 28,29 ST D2S1338: 16,25 ST D3S1358: 15,16 ST D5S818: 11 ST D7S820: 9,13 ST D8S1179: 10,11 ST FGA: 23,25 ST TH01: 7,8 ST TPOX: 8,11 ST vWA: 16,17 DI NCIt; C3224; Melanoma OX NCBI_TaxID=9606; ! Homo sapiens (Human) SX Male CA Cancer cell line DT Created: 22-10-12; Last updated: 10-04-25; Version: 11 // RX CelloPub=CLPUB00227; RA Daukste L.; RT "Mathematical modelling of cancer cell population dynamics."; RL Thesis PhD (2012); University of Canterbury; Christchurch; New Zealand. // RX PubMed=20041153; DOI=10.1371/journal.pone.0008461; PMCID=PMC2794539; RA Jeffs A.R., Glover A.C., Slobbe L.J., Wang L., He S.-J., Hazlett J.A., RA Awasthi A., Woolley A.G., Marshall E.S., Joseph W.R., Print C.G., RA Baguley B.C., Eccles M.R.; RT "A gene expression signature of invasive potential in metastatic RT melanoma cells."; RL PLoS ONE 4:e8461.1-e8461.11(2009). // RX PubMed=23658559; DOI=10.3389/fgene.2013.00066; PMCID=PMC3647113; RA Stones C.J., Kim J.E., Joseph W.R., Leung E.Y., Marshall E.S., RA Finlay G.J., Shelling A.N., Baguley B.C.; RT "Comparison of responses of human melanoma cell lines to MEK and BRAF RT inhibitors."; RL Front. Genet. 4:66.1-66.6(2013). // RX PubMed=32567790; DOI=10.1111/pcmr.12908; PMCID=PMC7818249; RA Tran K.B., Gimenez G., Tsai P., Kolekar S., Rodger E.J., RA Chatterjee A., Jabed A., Shih J.-H., Joseph W.R., Marshall E.S., RA Wang Q., Print C.G., Eccles M.R., Baguley B.C., Shepherd P.R.; RT "Genomic and signalling pathway characterization of the NZM panel of RT melanoma cell lines: a valuable model for studying the impact of RT genetic diversity in melanoma."; RL Pigment Cell Melanoma Res. 34:136-143(2021). //